What question did this study set out to answer?

To evaluate whether optical genome mapping enhances structural variant detection and refines risk stratification compared with standard chromosome banding analysis in myeloid neoplasms.

August 28, 2026npj Precision OncologyOpen Access

Optical genome mapping refines genomic risk stratification in therapy-related myeloid neoplasms and younger myelodysplastic syndromes

Q: What does this research mean for the field?

Optical genome mapping significantly improves the detection of genomic alterations and refines clinical risk stratification in therapy-related myeloid neoplasms and younger myelodysplastic syndromes compared to standard chromosome banding analysis. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Authors

JMJulia MestreUniversitat Autònoma de Barcelona LCLorea Chaparro‐GonzálezUniversitat Autònoma de Barcelona LPLucía Ruiz Pérez-HitaUniversitat Autònoma de Barcelona

Discussion

Member takes

Implication

Cohort study reveals optical genome mapping improves structural variant detection and risk stratification in myeloid neoplasms, highlighting its utility for guiding clinical prognosis.

Key Points

To evaluate whether optical genome mapping enhances structural variant detection and refines risk stratification compared with standard chromosome banding analysis in myeloid neoplasms.
Evaluated 113 patients comprising 48 with therapy-related myeloid neoplasms and 65 with younger myelodysplastic syndromes.
Integrated optical genome mapping (OGM) with conventional chromosome banding analysis (CBA), targeted next-generation sequencing, and longitudinal clinical data.
OGM was interpretable in 100% of cases and detected 134 additional genomic alterations (a 110% increase versus CBA), refining cytogenetic classification in 52.0% of abnormal karyotypes.
OGM uncovered relevant structural variants in 9.8% of CBA-normal cases and identified biallelic TP53 inactivation and chromoanagenesis associated with inferior overall survival.
Incorporate of OGM findings reclassified a subset of patients into higher-risk IPSS-R and IPSS-M categories, showing significant overall survival differences confirmed by multivariable Cox analysis.

Cite This Study

Mestre et al. (2026) studied this question.

synapsesocial.com/papers/6a9145ead15324a1df3a915c https://doi.org/10.1038/s41698-026-01671-z

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals optical genome mapping improves structural variant detection and risk stratification in myeloid neoplasms, highlighting its utility for guiding clinical prognosis.

Optical genome mapping refines genomic risk stratification in therapy-related myeloid neoplasms and younger myelodysplastic syndromes

Discussion

Member takes

Implication

Key Points

Cite This Study

Optical genome mapping refines genomic risk stratification in therapy-related myeloid neoplasms and younger myelodysplastic syndromes

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider